

LYNE FORTIN TO LEAVE THERATECHNOLOGIES BY YEAR-END

Montreal, Canada – September 28, 2018 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced that it was informed by Lyne Fortin, Senior Vice President and Chief Commercial Officer, that she will retire from the Company by year-end. Until then, she will remain in her position and will help in the transition of her files to her successor.

“I want to take this opportunity to thank Lyne for the significant contribution she made in making our Company become what it is today. Lyne brought the knowledge and experience that were needed to successfully make the transition towards becoming a commercial company and to help us launch Egrifta and Trogarzo™ in the United States,” said Luc Tanguay, President and Chief Executive Officer, Theratechnologies Inc.

“I am proud of what we accomplished as a team during my five-year tenure as Chief Commercial Officer. I want to thank everyone at Theratechnologies for giving me the privilege and pleasure to be a part of a Company that successfully reinvented itself. It is now time for me to pass on the torch to bring Theratechnologies to yet another milestone on the path of growth and profitability,” said Lyne Fortin, Senior Vice President and Chief Commercial Officer.

About Theratechnologies

Theratechnologies (TSX: TH) is a specialty pharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical conditions, including those living with HIV. Further information about Theratechnologies is available on the Company's website at www.theratech.com and on SEDAR at www.sedar.com.

Forward-Looking Information

This press release contains forward-looking statements and forward-looking information, or, collectively, forward-looking statements, within the meaning of applicable securities laws, that are based on our management's belief and assumptions and on information currently available to our management. You can identify forward-looking statements by terms such as “may”, “will”, “should”, “could”, “would”, “outlook”, “believe”, “plan”, “envisage”, “anticipate”, “expect” and “estimate” or the negatives of these terms, or variations of them.

Forward-looking statements are based upon a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Theratechnologies' control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information.

We refer potential investors to the “Risk Factors” section of our Annual Information Form dated February 6, 2018 available on SEDAR at www.sedar.com for additional risks and uncertainties about Theratechnologies and its business. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-looking statements reflect current expectations

regarding future events and speak only as of the date of this press release and represent our expectations as of that date. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law.

Media inquiries:

Denis Boucher

Vice President, Communications and Corporate Affairs

Tel.: (514) 336-7800